Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 80 clinical trials
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1) and to characterize the safety of the RP2R(s) for the study treatment (Part 2). The RP2R(s) will describe the combination doses and schedules of (tal+tec+dara) the treatment combinations …

human chorionic gonadotropin
carfilzomib
bortezomib
lenalidomide
refractory multiple myeloma
  • 2 views
  • 06 Jun, 2022
  • 13 locations
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

A phase II trial of continuous intravenous infusion of Blincyto given over a 28-day cycle. Starting day for patients who are MRD-positive before HSCT is between day +60 and day +100 and for patients who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT. Patients …

  • 0 views
  • 19 Mar, 2021
  • 14 locations
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

  • 0 views
  • 11 May, 2022
  • 13 locations
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).

immunoglobulin a
nephritis
angiotensin
proteinuria
immunosuppression
  • 4 views
  • 25 Dec, 2021
  • 63 locations
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.

glomerular filtration rate
immunoglobulin a
proteinuria
nephropathy
immunoglobulins
  • 486 views
  • 05 Mar, 2022
  • 30 locations
Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

type 2 diabetes
ras inhibitor
corticosteroids
kidney function tests
diabetes
  • 17 views
  • 17 Jun, 2022
  • 32 locations
Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

renal function
nephropathy
  • 33 views
  • 17 Jun, 2022
  • 119 locations
Outpatient Treatment With Anti-Coronavirus Immunoglobulin (OTAC)

The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed SARS-CoV-2 infection who do not require hospitalization. The primary endpoint of this …

  • 0 views
  • 24 Apr, 2022
  • 34 locations
Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies (TINISS)

To summarise, the peripheral neurological complications experienced by patients with primary Sjögren's syndrome are particularly bothersome since they are common and often result in significant disability related to pain or motor impairment. There is currently no standard treatment for these patients. As these neuropathies are caused by an immune system …

  • 0 views
  • 09 May, 2022
  • 1 location
Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins (HBIG)

This is an open-label, single arm (two cohorts), single-center, phase II pilot-study to provide preliminary evidence whether hepatitis B immunoglobulins (HBIG) are efficacious and can be safely

hepatitis
hepatitis b immune globulin
  • 0 views
  • 16 Jun, 2022
  • 1 location